Politicians urge Obama to allow public review of IP provisions in TPP

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Politicians urge Obama to allow public review of IP provisions in TPP

Six members of US Congress have written to US President Barack Obama expressing concern that "secret" negotiations over intellectual property in the Trans Pacific Partnership (TPP) Agreement benefit pharmaceutical companies at the expense of public health.

The six Democrats - Jan Schakowsky (Illonois), Michael Michaud (Maine), Rosa DeLauro (Conneticut), George Miller (California), Barbara Lee (California) and Peter Welch (Vermont) - said the current proposals would have "profound and long-lasting consequences".

In the letter, sent yesterday, the Members urged Obama not to make any final trade agreements "that affect critical health issues" until members of the public and Congress have had the opportunity to review the provisions and provide input.

In particular, they argued that proposed provisions relating to data exclusivity, patent registration and procedure and enforcement would "delay generic competition and increase the price of medicine" and lead to "preventable illnesses and deaths".

"Certainly, trade negotiations conducted behind closed doors are not the place to make changes that would have such profound consequences for patents and veterans, as well as state and federal budgets," they wrote.

Although the TPP negotiations were meant to have been conducted in secret, whistleblowing website WikiLeaks has released several documents which suggest the US is exerting "great pressure" on other nations to adopt stricter IP policies. In the latest release, yesterday, WikiLeaks published two leaked documents that suggest that the US is isolated in its positions on many IP policies.

more from across site and SHARED ros bottom lb

More from across our site

Sim & San secured the win for Dr. Reddy’s, which will allow the pharma company to manufacture and export semaglutide, the active ingredient in Ozempic
Lucas Amodio joins our ‘Five minutes with’ series to discuss artificial intelligence systems and patent law
The Americas research cycle has commenced, so don't miss the opportunity to submit your work
Practitioners have welcomed extended funding of the specialist police unit until 2029, while the UKIPO says it is exploring increased scale
Abion says integration with Baylos marks an important step in the company’s international expansion plans
Via Licensing Alliance continues its China push as another smartphone manufacturer joins patent pool as licensee
Law firm mergers have the potential to reshape IP teams, and partners who were at the coalface of previous tie-ups say early coordination and flexibility can make the difference
Women are entering the IP profession, but still too few are being trusted with the clients, cases, and credit that may open the path to leadership
In other news, Australia’s IP office has announced expanded search options, and an EPO report shed light on slow progress relating to women inventors in Europe
Managing IP speaks with up-and-coming women lawyers at five law firms about fighting imposter syndrome, maintaining work-life balance and why real representation matters
Gift this article